KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial. PMID 39706350 · Gastroenterology · 2025-Apr The study is a randomized, oncology trial reporting a primary result, but it is excluded because the intervention is non-drug (endoscopic screening) and the outcome is not a standard time-to-event efficacy endpoint (e.g., OS, PFS) as defined by the inclusion criteria. No phase information is provided to confirm it is a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. PMID 39700456 · J Clin Oncol · 2025-Apr The study is a Phase III, randomized-controlled trial (RCT) of a drug in oncology, but it is a single-arm trial and the primary endpoint is objective response rate (ORR), not a time-to-event endpoint like OS, PFS, or DFS. The abstract does not report Kaplan-Meier curves or hazard ratios for any time-to-event outcome. Therefore, it does not meet the core requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer. PMID 39694415 · J Thorac Oncol · 2025-Apr This is an original Phase III randomized trial with an oncology focus, but the primary endpoint is time to treatment initiation (TTI), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis of such. Furthermore, the intervention is a diagnostic procedure (liquid biopsy), not a drug-containing intervention. Therefore, it does not meet the eligibility criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial. PMID 39676623 · Ann Neurol · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). PMID 39674398 · Int J Infect Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. PMID 39648559 · Liver Int · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR. PMID 39645016 · J Heart Lung Transplant · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. PMID 39608389 · Lancet Infect Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality. PMID 39601354 · Liver Int · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. PMID 39592058 · J Am Acad Dermatol · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials. PMID 39581330 · Ophthalmology · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Laparoscopic suture-free partial nephrectomy using argon-beam-coagulator: Surgical technique and outcomes of a single-center, open-label randomized controlled trial. PMID 39578201 · Urol Oncol · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD. PMID 39521398 · Am J Kidney Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study. PMID 39521012 · Lancet Infect Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pragmatic monitoring of emerging efficacy data in randomized controlled trials. PMID 39520228 · Clin Trials · 2025-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. PMID 39447871 · Ophthalmol Retina · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. PMID 39406613 · Eur Urol Oncol · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting. PMID 39394852 · Clin Trials · 2025-Apr The record is a methodological article discussing the design of non-inferiority trials, not an original report of a completed randomized Phase III or II/III clinical trial with drug intervention results. It meets oncology, human, randomized, phase3, and time_to_event signals but is excluded because it is not an original trial result report and lacks a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder. PMID 39394672 · Subst Use Addctn J · 2025-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial. PMID 39389463 · Ophthalmol Retina · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. PMID 39384451 · Eur Urol Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical trials involving rare gynaecological cancers. PMID 39358159 · Eur J Surg Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions. PMID 39327187 · Eur Urol Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome. PMID 39315857 · J Eur Acad Dermatol Venereol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials. PMID 39292389 · Clin Transl Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial. PMID 38764430 · J Chemother · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. PMID 38688767 · Eur Urol Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Atorvastatin and left atrial function during anthracycline-based chemotherapy. PMID 40876541 · J Cardiovasc Magn Reson · 2025 Win 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial. PMID 40982703 · J Clin Psychopharmacol · 2025 Nov 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aprocitentan: The First Endothelin Receptor Antagonist for Resistant Hypertension. PMID 40638911 · Am J Ther · 2025 Nov 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial. PMID 40193234 · J Addict Med · 2025 Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. PMID 39629836 · J Addict Med · 2025 May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effectiveness of Integrated Mindfulness-Based Fitness Training Program in Ameliorating Physical Symptoms and Survivor Concerns in Patients With Breast Cancer: A Randomized Clinical Trial. PMID 38158601 · Cancer Nurs · 2025 May The study is a randomized controlled trial in oncology (breast cancer) but does not meet key eligibility criteria: it lacks a drug intervention, is not definitively a Phase III/IIIb or Phase II/III trial, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Experimental Study of Ultra-Pulsed CO 2 Fractional Laser Combined With Recombinant Human Epidermal Growth Factor Gel in the Treatment of Eyelid Keloid. PMID 39197180 · Ophthalmic Plast Reconstr Surg · 2025 Mar The record describes a randomized trial of a drug-containing intervention (rHEGF gel) for eyelid keloid, which is not a malignant neoplasm. Furthermore, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recent Advancements and Future Perspectives on Molecular Biomarkers in Adult Lower-Grade Gliomas. PMID 39841423 · Cancer J · 2025 Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating bowel preparation tolerability in IBD: a phase 3 post-hoc comparison of mannitol and PEG-ASC. PMID 41822289 · Front Gastroenterol (Lausanne) · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ablatio-bilica: safety of biliary intraductal radiofrequency ablation in patients with unresectable extrahepatic biliary tract cancer undergoing systemic anti-tumor therapy: a phase II, multi-center, randomized, and controlled study. PMID 41816011 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Target trial emulation in oncology: current use and future directions. PMID 41810148 · Mil Med Res · 2025 This is a review article discussing the use and challenges of target trial emulation in oncology. It is not a primary result report of an individual, randomized, drug-intervention Phase III trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism. PMID 41716487 · Front Endocrinol (Lausanne) · 2025 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Multimodal prehabilitation enhances perioperative outcomes in gastric cancer patients: a single-center randomized controlled trial. PMID 41710593 · Front Nutr · 2025 The record describes a randomized trial of a non-drug, multimodal prehabilitation (exercise, nutrition, psychological support) for gastric cancer patients undergoing surgery. The primary endpoint is 30-day complication rate, with secondary endpoints of functional recovery and patient-reported outcomes. There is no drug intervention, and no time-to-event efficacy endpoint (OS, PFS, DFS, etc.) is reported. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial. PMID 41647109 · Front Endocrinol (Lausanne) · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis. PMID 41635404 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial. PMID 41624863 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer. PMID 41613047 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China. PMID 41601703 · Front Urol · 2025 干预为非药物单独策略,未满足药物干预要求。
H B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial. PMID 41601631 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Incidence and risk assessment of thyroid dysfunction following immune checkpoint inhibitor therapy: a systematic review and meta-analysis. PMID 41552314 · Am J Transl Res · 2025 The record is a systematic review/meta-analysis of phase II/III RCTs. While it synthesizes data from multiple oncology trials with drug interventions, it is not an original trial report itself. Furthermore, its outcome of interest (incidence of thyroid dysfunction) is a safety/toxicity endpoint, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of a pubic superior ramus approach versus a distal approach for obturator nerve block in transurethral bladder tumor resection: a randomized controlled trial. PMID 41552287 · Am J Transl Res · 2025 The study is an oncology RCT in humans with a primary result, but it does not meet all required eligibility criteria: (1) the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata; (2) the intervention is a surgical/anesthetic technique (obturator nerve block approach) without a drug-containing intervention as the primary comparator; (3) the primary efficacy endpoint is not a time-to-event endpoint. Therefore, is_eligible is false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
From trial to real life: ten-year impact of a nutraceutical strategy on duodenal polyp burden in familial adenomatous polyposis. PMID 41551144 · Front Oncol · 2025 The study is a prospective cohort, not a randomized trial, and evaluates a nutraceutical supplement with continuous outcomes (polyp burden), lacking the required randomized drug intervention and time-to-event endpoint for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 41550955 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -